«Possibilities of a unified approach to the treatment of IgE-associated respiratory diseases. Clinical Experience exchange».
- Authors: Ukhanova O.P.1, Karamishev D.V.2, Ryabova K.A.3, Hanova F.4
-
Affiliations:
- Stavropol Regional Clinical Hospital
- Moscow Regional Research Clinical Institute named by M.F. Vladimirskiy
- The First Sechenov Moscow State Medical University
- The National Medical Research Center for Otorhinolaryngology of the Federal Medico-Biological Agency of Russia
- Issue: Vol 18, No 2 (2021)
- Pages: 138-148
- Section: Case reports
- URL: https://rusalljournal.ru/raj/article/view/1456
- DOI: https://doi.org/10.36691/RJA1456
Cite item
Abstract
Inflammatory diseases of the upper and lower respiratory airways, such as allergic rhinitis, nasal polyposis, bronchial asthma have common proinflammatory mechanisms, mediated by IgE-dependent cascade of inflammation. Concurrent existence of asthma and allergic rhinitis and/or nasal polyposis increases clinical symptoms severity, disease course aggravation and eventually disease control loss for the patient. Anti-IgE-therapy is pathogenetically justified effective and safe therapeutic option for various patient groups. Today principles of interdisciplinary approach are in practice to target upper and lower respiratory diseases management, which determines the success of biological therapy. ENT, pulmonology and allergy specialists define patient management tactics in close collaboration taking into consideration diseases manifestation. The proven efficacy and safety of оmalizumab makes this drug a universal tool to achieve IgE-associated diseases control and an alternative solution for surgical intervention and therapy with systemic corticosteroids.
Full Text

About the authors
Olga P. Ukhanova
Stavropol Regional Clinical Hospital
Author for correspondence.
Email: uhanova_1976@mail.ru
ORCID iD: 0000-0002-7247-0621
SPIN-code: 8287-2891
MD, Dr. Sci. (Med.), Professor
Russian Federation, StavropolDmitrii V. Karamishev
Moscow Regional Research Clinical Institute named by M.F. Vladimirskiy
Email: d.v.karamyshev@bk.ru
ORCID iD: 0000-0002-1323-4821
SPIN-code: 9930-2075
MD
Russian Federation, MoscowKseniya A. Ryabova
The First Sechenov Moscow State Medical University
Email: acksinja@gmail.com
ORCID iD: 0000-0003-0520-0936
SPIN-code: 9000-6894
MD, Research Associate
Russian Federation, MoscowFatimat Hanova
The National Medical Research Center for Otorhinolaryngology of the Federal Medico-Biological Agency of Russia
Email: fmkhanova@yahoo.com
ORCID iD: 0000-0001-9362-9139
SPIN-code: 5320-2821
MD, Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Palomares Ó, Sánchez-Ramón S, Dávila I, et al. dIvergEnt: How IgE axis contributes to the continuum of allergic asthma and anti-ige therapies. Int J Mol Sci. 2017;18(6):1328. doi: 10.3390/ijms18061328
- Cheng SL. Immunologic pathophysiology and airway remodeling mechanism in severe asthma: focused on IgE-Mediated pathways. Diagnostics (Basel). 2021;11(1):83. doi: 10.3390/diagnostics11010083
- Phillips KM, Hoehle LP, Caradonna DS, et al. Association of severity of chronic rhinosinusitis with degree of comorbid asthma control. Ann Allergy Asthma Immunol. 2016;117(6):651–654. doi: 10.1016/j.anai.2016.09.439
- Leynaert B, Neukirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106(5 Suppl):S201–205. doi: 10.1067/mai.2000.110151
- Allergic rhinitis: clinical recommendations (Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation). RAAKI; 2020. (In Russ). Avalable from: https://raaci.ru/education/clinic_recomendations/471.html
- Giavina-Bianchi P, Aun MV, Takejima P, et al. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. doi: 10.2147/JAA.S81541
- Humbert M, Bousquet J, Bachert C, et al. IgE-Mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418–1429. doi: 10.1016/j.jaip.2019.02.030
- Okubo K, Okano M, Sato N, et al. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. J Allergy Clin Immunol Pract. 2020; 8(9):3130-3140.e2. doi: 10.1016/j.jaip.2020.04.068
- Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi: 10.1016/j.jaci.2020.05.032
- Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2(3):332–40.e1. doi: 10.1016/j.jaip.2014.02.001
- Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196–208. doi: 10.1177/1945892419884774
- Ukhanova OP, Dzhabarova AA, Sivun IV, Buryndina EI. Prospects of gene-engineering therapy of seasonal allergic rhinitis of severe course. Bulletin of Modern Clinical Medicine. 2018;11(2):36–40. (In Russ). doi: 10.20969/VSKM.2018.11(2).36-40.
Supplementary files
